Notably, patients with p16+ oropharyngeal carcinoma demonstrated better three-year PFS and overall survival compared to those with p16- oropharyngeal carcinoma, while tumor EGFR expression did not significantly affect the outcome (48). The gene discussed is EGFR; the disease is oropharyngeal carcinoma.